false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Advance ...
Immune Response to AAV in Human Kidney Organoids
Immune Response to AAV in Human Kidney Organoids
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Hiroyuki Nakai described efforts to develop AAV gene therapy for Alport syndrome, a progressive genetic kidney disease caused by mutations in type IV collagen genes. Because the full COL4A5 gene exceeds AAV’s packaging capacity and podocytes are difficult to target, the team developed a dual-AAV split-intein approach to reconstitute full-length collagen in cells. They demonstrated collagen production and deposition in the glomerular basement membrane, but conventional AAV9 reached too few podocytes to achieve a cure.<br /><br />To improve delivery, the researchers computationally designed novel AAV capsids. AAVYT1 substantially increased podocyte transduction and collagen deposition compared with AAV9 in mice; a liver-detargeted version retained meaningful podocyte targeting. The team is preparing to evaluate dual-AAV treatment in a dog model of Alport syndrome.<br /><br />Nakai also reviewed alternative strategies for fitting or restoring the large genetic payload, including exon skipping, stop-codon read-through, and other dual-vector methods. He emphasized that challenges remain, including dose, off-target transduction, immune responses, and achieving sufficiently broad collagen restoration.
Asset Caption
Ryuji Morizane, MD, PhD
Meta Tag
Speaker
Ryuji Morizane
Keywords
Alport syndrome
AAV gene therapy
COL4A5
dual-AAV split-intein
podocyte transduction
AAV capsid engineering
collagen deposition
Ryuji Morizane
×
Please select your language
1
English